Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Chronic endometritis is infectious in nature and thus benefits from treatment with antibiotics, according to a study.

Antibiotic therapy fights chronic endometritis

Type 1 diabetes risk up in first 180 days after influenza diagnosis

Influenza may trigger an increase in the likelihood of developing type 1 diabetes, a new Japan study has found.

Type 1 diabetes risk up in first 180 days after influenza diagnosis

VTE incidence in COVID-19 patients in Sg ICUs lower than expected

A lower than expected incidence of venous thromboembolism (VTE) among ICU*-admitted patients with COVID-19, as shown in a retrospective observational study from Singapore, suggests the need to rethink thromboprophylaxis strategies in this setting.

VTE incidence in COVID-19 patients in Sg ICUs lower than expected

Inflammation strongly signals CV events in treated female vs male HIV patients

For HIV patients treated with antiretroviral therapy (ART), higher levels of inflammatory biomarkers help predict non-AIDS cardiovascular (CV) events more strongly in women than men, according to a study.

Inflammation strongly signals CV events in treated female vs male HIV patients

Oral FMT capsules safe, effective for recurrent C. difficile infection

Oral faecal microbiota transplantation (FMT) capsules for recurrent Clostridioides difficile infection (rCDI) appear more favourable than FMT through colonoscopy because of ease of administration and its noninvasive delivery, a study has shown.

Oral FMT capsules safe, effective for recurrent C. difficile infection

ART initiation improves long-term depression symptoms in acute HIV

Improvements in depression symptoms remain stable at 6 years in individuals who maintain viral suppression after antiretroviral therapy (ART) during acute HIV-1 infection (AHI), according to a Thai study presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2021.

ART initiation improves long-term depression symptoms in acute HIV

Dolutegravir-lamivudine shows durable efficacy for HIV across patient subgroups

Treatment-naïve individuals with HIV continued to benefit from the dolutegravir-lamivudine regimen for nearly 3 years regardless of baseline disease characteristics and demographics, as shown by its noninferiority to dolutegravir plus tenofovir and emtricitabine observed in the subgroup analyses of the GEMINI trials presented at CROI 2021.

Dolutegravir-lamivudine shows durable efficacy for HIV across patient subgroups